{"questions": [
    {
        "body": "Are there any DNMT3 proteins present in plants?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/CMT1_ARATH", 
            "http://www.uniprot.org/uniprot/CMT2_ARATH", 
            "http://www.uniprot.org/uniprot/CMT3_ARATH"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21150311", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15946751", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20505370", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23021223", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22058406", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18488247", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17660570", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11487702", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11459824", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15282033", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12151602", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12121623", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9584105"
        ], 
        "exact_answer": "Yes", 
        "id": "511a16f9df1ebcce7d000005", 
        "ideal_answer": "Yes. The plant DOMAINS REARRANGED METHYLTRANSFERASE2 (DRM2) is a homolog of the mammalian de novo methyltransferase DNMT3. DRM2 contains a novel arrangement of the motifs required for DNA methyltransferase catalytic activity.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150311", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 151, 
                "text": "De novo DNA methylation in Arabidopsis thaliana is catalyzed by the methyltransferase DRM2, a homolog of the mammalian de novo methyltransferase DNMT3."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1131, 
                "offsetInEndSection": 1666, 
                "text": "Three functional classes of DNA methyltransferase exist in A.thaliana; METHYLTRANSFERASE1 (MET1) (orthologous to mammalian Dnmt1) which maintains CG methylation, CHROMOMETHYLASE3 (CMT3) (plant specific) which maintains methylation in non-CG sequence contexts and DOMAINS REARRANGED METHYLTRANSFERASE2 (DRM2) (orthologous to Dnmt3a/Dnmt3b) which both de novo methylates DNA and maintains non-CG methylation redundantly with CMT3 [2]. The drm2 mutation blocks all de novo DNA methylation driven by repeat containing transgenes [15]\u2013[17]."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2763, 
                "offsetInEndSection": 2909, 
                "text": "The mammalian DRM2 orthologs, Dnmt3a and Dnmt3b, are required to de novo methylate integrated retroviral sequences and imprinted genes [38], [39]."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 387, 
                "offsetInEndSection": 851, 
                "text": "Here we describe DNA methyltransferase genes from both Arabidopsis and maize that show a high level of sequence similarity to Dnmt3, suggesting that they encode plant de novo methyltransferases. Relative to all known eukaryotic methyltransferases, these plant proteins contain a novel arrangement of the motifs required for DNA methyltransferase catalytic activity. The N termini of these methyltransferases contain a series of ubiquitin-associated (UBA) domains. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15946751", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 365, 
                "offsetInEndSection": 519, 
                "text": "BLASTX searches and phylogenetic analysis suggested that five cDNAs belonged to four classes (Dnmt1, Dnmt2, CMT and Dnmt3) of DNA methyltransferase genes."
            }
        ], 
        "type": "yesno"
    },
    {
        "body": "Is thrombophilia related to increased risk of miscarriage?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019851", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011248", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011256", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011255", 
            "http://www.disease-ontology.org/api/metadata/DOID:10591", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007565"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22543699", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22164918", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21380983", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7986734", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19135285", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18845284", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16962918", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15713144", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19165673", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20860491"
        ], 
        "exact_answer": "Yes", 
        "id": "513cdc38bee46bd34c000007", 
        "ideal_answer": "Thrombophilia has been found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period. In particular there is an increased risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22543699", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1065, 
                "offsetInEndSection": 1159, 
                "text": "Thrombophilia does hardly increase the risk of IUGR/PMPC or if so, it can be prevented by LMWH"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164918", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 571, 
                "offsetInEndSection": 796, 
                "text": "for illustrative purposes, a patient presenting with combined thrombophilia--both genetic and acquired--will be discussed. This patient had suffered severe gestational complications that led to devastating obstetrical outcome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21380983", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 235, 
                "text": "Thrombophilias have been implicated in complications related to ischemic placental disease including recurrent pregnancy loss, intrauterine fetal demise, preeclampsia, fetal growth restriction, placental abruption, and preterm delivery"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7986734", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 905, 
                "offsetInEndSection": 1061, 
                "text": "Further information about the combined risk of aPC resistance and pregnancy is needed before guidance on the management of affected women can be formulated."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 148, 
                "offsetInEndSection": 263, 
                "text": "Thrombotic risk during pregnancy and the puerperium is higher in asymptomatic women with than without thrombophilia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 734, 
                "offsetInEndSection": 870, 
                "text": "Further studies are required to assess the thrombotic risk in women with preeclampsia as well as early or late recurrent pregnancy loss."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 89, 
                "text": "Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1265, 
                "offsetInEndSection": 1532, 
                "text": "In conclusion, homozygous carriers of factor V Leiden and, to a lesser extent, double heterozygous carriers of factor V Leiden and of the prothrombin mutation have an increased risk of venous thrombosis during pregnancy, particularly high during the postpartum period"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135285", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 767, 
                "offsetInEndSection": 873, 
                "text": "Careful diagnosis, observation and monitoring can add significant benefit to LMWH therapy during pregnancy"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 142, 
                "text": "Pregnancy in healthy women is accompanied by hypercoagulable changes that may interact with thrombophilia risk factors and threaten pregnancy."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1239, 
                "offsetInEndSection": 1444, 
                "text": "Fifty-three (13 %) women had antiphospholipid antibodies (lupus anticoagulant and/or anti-beta2-glycoprotein 1 antibodies) mainly associated with the risk of spontaneous abortion during the first trimester"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1461, 
                "offsetInEndSection": 1713, 
                "text": "thrombophilia was found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845284", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1104, 
                "offsetInEndSection": 1262, 
                "text": "When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962918", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 604, 
                "offsetInEndSection": 779, 
                "text": "knowledge combined with the appropriate use of thromboprophylaxis and treatment in women who have objectively confirmed VTE continue to improve maternal and perinatal outcomes"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15713144", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1508, 
                "offsetInEndSection": 1666, 
                "text": "The risk of having thrombophilia is doubled in men who have fathered pregnancies which ended in perinatal death as well as in the mothers of such pregnancies."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165673", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 560, 
                "offsetInEndSection": 707, 
                "text": "The prevalence of thrombophilic variants is of possible public health significance for other morbidity; but perhaps not in relation to preeclampsia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860491", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 694, 
                "offsetInEndSection": 826, 
                "text": "This study suggests that thrombophilia \"mediates\" in lowering of cardiovascular risk factors in women with a history of preeclampsia"
            }
        ], 
        "type": "yesno"
    },
    {
        "body": "Is Mammaprint approved by the United States Food and Drug Administration?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017321", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017322", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017327"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19879448", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19546609", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18515733", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17462970"
        ], 
        "exact_answer": "Yes", 
        "id": "51487821d24251bc0500002f", 
        "ideal_answer": "Yes, Mammaprint has been approved by the US Food and Drug Administration.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1432, 
                "offsetInEndSection": 1485, 
                "text": "an FDA-cleared 70-gene signature of MammaPrint panel "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19879448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 460, 
                "offsetInEndSection": 562, 
                "text": "on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546609", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1614, 
                "offsetInEndSection": 1862, 
                "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1806, 
                "offsetInEndSection": 1909, 
                "text": "MammaPrint from Agendia are the first FDA approved microarray-based tests for diagnostic applications. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 2899, 
                "offsetInEndSection": 3099, 
                "text": "MammaPrint is the first FDA approved, gene expression-based prognostic test which assess patients\u2019 risk for distant metastasis in women under age 61 with Stage I-II lymph node negative breast cancer. "
            }, 
            {
                "beginSection": "sections.3", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
                "endSection": "sections.3", 
                "offsetInBeginSection": 4677, 
                "offsetInEndSection": 4869, 
                "text": "The Amsterdam 70-gene expression signature as breast cancer prognosis marker has been validated in follow-up studies [39,40], and a clinical assay MammaPrint\u00ae has recently been cleared by FDA."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18515733", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1391, 
                "offsetInEndSection": 1785, 
                "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the U.S. Food and Drug Administration, a larger gene number, which may enhance further utility, and a potentially wider patient eligibility, including lymph node-positive, estrogen receptor (ER)-negative, and younger patients being accrued into the prospective trial (Microarray in Node-Negative Disease May Avoid Chemotherapy). "
            }
        ], 
        "triples": [
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A17680439", 
                "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                "s": "http://linkedlifedata.com/resource/umls/id/C2827401"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4434464B59390011"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_51395844503300D"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4F383737393600D"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4530503539300011"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Does the Oncotype DX test work with paraffin embedded tissues?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016612"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16361546"
        ], 
        "exact_answer": "Yes", 
        "id": "514a0f0ad24251bc05000052", 
        "ideal_answer": "Yes, the Oncotype DX test works with paraffin embedded tissue.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2732, 
                "offsetInEndSection": 3135, 
                "text": "The Oncotype-DX Breast Cancer Assay (Genomic Health, Redwood City, CA) quantifies gene expression for 21 genes in breast cancer tissue by performing reverse transcription polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) tumour blocks that are obtained during initial surgery (lumpectomy, mastectomy, or core biopsy) of women with early breast cancer that is newly diagnosed."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 211, 
                "offsetInEndSection": 546, 
                "text": "Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 250, 
                "text": "Oncotype DX is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 512, 
                "offsetInEndSection": 578, 
                "text": "We therefore investigated the analytical performance of the assay."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 588, 
                "offsetInEndSection": 848, 
                "text": "Assays used a pooled RNA sample from fixed paraffin-embedded tissues to evaluate the analytical performance of a 21-gene panel with respect to amplification efficiency, precision, linearity, and dynamic range, as well as limits of detection and quantification."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 726, 
                "offsetInEndSection": 960, 
                "text": "One such strategy is the 21-gene assay (Oncotype DX), which is currently in commercial use in the USA. One advantage of this test is the use of paraffin-embedded blocks instead of previous methods, which required fresh frozen tissue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 119, 
                "offsetInEndSection": 263, 
                "text": "We used paraffin-embedded core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 590, 
                "offsetInEndSection": 700, 
                "text": "In addition to the individual genes, the correlation of the Oncotype DX Recurrence Score with pCR was examined"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 377, 
                "offsetInEndSection": 415, 
                "text": "RNA was extracted from paraffin blocks"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 55, 
                "offsetInEndSection": 114, 
                "text": "to develop the 21-gene Recurrence Score assay (Oncotype DX)"
            }
        ], 
        "triples": [
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A7572812"
            }, 
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A9424108", 
                "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                "s": "http://linkedlifedata.com/resource/umls/id/C0030415"
            }, 
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A17999423"
            }, 
            {
                "o": "PARAFFIN", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A8438050"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A16755941"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Is depression associated with poor prognosis of brain tumor patients?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001932", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011379", 
            "http://www.disease-ontology.org/api/metadata/DOID:1319", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016019", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017063"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15072475"
        ], 
        "exact_answer": "Yes", 
        "id": "514cc8dcd24251bc05000066", 
        "ideal_answer": "Yes. In brain tumor patients depression is associated with shorter survival and worse functional outcomes.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 583, 
                "offsetInEndSection": 820, 
                "text": "Before surgery 27 patients (35%) had BDI scores indicating the presence of depression. These scores were significantly higher in patients with a history of depression (p = 0.017) and in those with a lower functional outcome (p = 0.015). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 949, 
                "offsetInEndSection": 1129, 
                "text": "A lower functional status (KPS score < or = 70) in patients was significantly associated with high depression scores at the 3-month (p = 0.000) and 1-year (p = 0.005) assessments. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 782, 
                "offsetInEndSection": 965, 
                "text": "At all follow-ups, depressed low-grade glioma patients had a significantly shorter survival time, 3.3-5.8 years, compared to non-depressed low-grade glioma patients, 10.0-11.7 years. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1083, 
                "offsetInEndSection": 1224, 
                "text": "The results suggest that depression and decreased QOL among low-grade glioma patients is related to shorter survival at long-term follow-up. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 144, 
                "text": "The adverse impact of depression in relation to survival among cancer patients is currently a subject of great interest in research. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1192, 
                "offsetInEndSection": 1388, 
                "text": " In the subgroup of patients with low-grade gliomas, depressive patients had a significantly shorter survival time compared with nondepressive subjects (P = 0.031, Kaplan-Meier survival analysis)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1731, 
                "offsetInEndSection": 1848, 
                "text": "Preoperative depression seemed to be a significant prognostic factor for worse survival in low-grade glioma patients."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072475", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1075, 
                "offsetInEndSection": 1245, 
                "text": "Major depressive disorder was marginally associated with outcomes, while surgical interventions and radiotherapy did not show strong associations with test performances. "
            }
        ], 
        "type": "yesno"
    },
    {
        "body": "Does HER2 under-expression lead to favorable response to trastuzumab?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020869", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786", 
            "http://www.biosemantics.org/jochem#4002084", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005176", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038128", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010467", 
            "http://www.disease-ontology.org/api/metadata/DOID:0060079", 
            "http://www.disease-ontology.org/api/metadata/DOID:0060080"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23082154", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22658319", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22580986", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21709140", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20392785", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19920112", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19624808", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19606230", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19435924", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18534031", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12503030", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11148461"
        ], 
        "exact_answer": "No", 
        "id": "51542eacd24251bc05000084", 
        "ideal_answer": "No, trastuzumab is effective only in cancers where Her2 is over-expessed.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23082154", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 961, 
                "offsetInEndSection": 1117, 
                "text": "trastuzumab (Herceptin\u00ae) an antibody-based therapy exists which is successfully used clinically for targeting HER2 in metastatic HER2-positive breast cancer"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 211, 
                "offsetInEndSection": 331, 
                "text": "over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 526, 
                "offsetInEndSection": 802, 
                "text": "In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658319", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 348, 
                "offsetInEndSection": 408, 
                "text": "treatment of HER2-overexpressing breast cancer: trastuzumab,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580986", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 173, 
                "offsetInEndSection": 354, 
                "text": "Trastuzumab has demonstrated clinical activity in several types of HER2-overexpressing epithelial tumors, such as breast and metastatic gastric or gastroesophageal junction cancer. "
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21709140", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 7981, 
                "offsetInEndSection": 8131, 
                "text": "trastuzumabThe Panel unanimously supported the use of 1 year of trastuzumab as standard adjuvant treatment for patients with \u2018HER2 positive\u2019 disease, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392785", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1621, 
                "offsetInEndSection": 1817, 
                "text": "An example is the established benefit of trastuzumab as adjuvant therapy for breast cancer; a clear definition of HER2-positivity and the assay reproducibility have, however, remained unanswered. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920112", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 136, 
                "text": "Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624808", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 400, 
                "offsetInEndSection": 587, 
                "text": "Without contraindication HER2 protein overexpression (or HER2 gene amplification) represents the worldwide accepted rationale for antibody-targeted therapy using trastuzumab (Herceptin\u2122)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606230", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 153, 
                "offsetInEndSection": 341, 
                "text": " anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin\u00ae), the first immunotherapeutic drug for the successful treatment of breast carcinomas overexpressing the HER2 (erbB-2) oncogene ["
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435924", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 350, 
                "text": "Human epidermal growth factor receptor 2 (HER2/neu) is an important target for the treatment of the breast cancers in which it is overexpressed. However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization-negative)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18534031", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 570, 
                "offsetInEndSection": 724, 
                "text": "effective targeted therapies such as Trastuzumab (Herceptin), a monoclonal antibody to HER2, which are effective only in tumors with HER2 overexpression, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503030", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 146, 
                "text": "The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) is useful in the treatment of ErbB2-overexpressing breast cancers,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148461", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 280, 
                "text": "HercepTestTM (DAKO A/S, Glostrup, Denmark) is an immunohistochemical assay that detects HER2/neu gene products, and evaluates the overexpression status of the HER2/neu protein in determining eligibility for the Trastuzumab (HerceptinR, Genentech, San Francisco, CA, USA) therapy. "
            }
        ], 
        "triples": [
            {
                "o": "Trastuzumab", 
                "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00072"
            }, 
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A10771788", 
                "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                "s": "http://linkedlifedata.com/resource/umls/id/C0728747"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A10771788"
            }, 
            {
                "o": "trastuzumab", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A1545807"
            }, 
            {
                "o": "TRASTUZUMAB", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A8438296"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A1545806"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001798", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016229", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023582", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001773", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23054683", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22155483", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21709374", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23528227"
        ], 
        "exact_answer": "Yes", 
        "id": "5156beb4d24251bc05000089", 
        "ideal_answer": "Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23054683", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 469, 
                "offsetInEndSection": 783, 
                "text": "miRNAs are aberrantly expressed in AD, and these have been implicated in the regulation of amyloid-\u03b2 (A\u03b2) peptide, tau, inflammation, cell death, and other aspects which are the main pathomechanisms of AD. In addition, regulation of miRNAs varies in blood, and cerebral spinal fluid may indicate alterations in AD."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 251, 
                "offsetInEndSection": 407, 
                "text": "miRNA microarray analysis was carried out on blood of rats at 1 week and 2 months after injection. RESULTS: Many up- and downregulated miRNAs were detected."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 536, 
                "offsetInEndSection": 712, 
                "text": "Blood miRNAs could be useful as biomarkers for exposure to nanoparticles. miR-298 regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1) in Alzheimer's disease."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155483", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 115, 
                "offsetInEndSection": 484, 
                "text": " We previously studied microRNAs (miRNAs) in AD autopsy brain samples and reported a connection between miR-137, -181c, -9, -29a/b and AD, through the regulation of ceramides. In this study, the potential role of these miRNAs as diagnostic markers for AD was investigated. We identified that these miRNAs were down-regulated in the blood serum of probable AD patients. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 173, 
                "offsetInEndSection": 399, 
                "text": "287 with Alzheimer disease (AD) as compared with 344 age- and gender-matched controls. In addition, we evaluated expression levels of hnRNP-A1 and its regulatory microRNA (miR)-590-3p in blood cells from patients and controls."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1240, 
                "offsetInEndSection": 1470, 
                "text": "Decreased relative expression levels of hsa-miR-590-3p was observed in patients with AD versus controls (0.685\u2009\u00b1\u20090.080 versus 0.931\u2009\u00b1\u20090.111, p\u2009=\u20090.079), and correlated negatively with hnRNP-A1 mRNA levels (r\u2009=\u2009-0.615, p\u2009=\u20090.0237)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1630, 
                "offsetInEndSection": 1891, 
                "text": ".Gene expression studies in AD have shown substantial downregulation of various mRNA species in brain (Pasinetti, 2001), peripheral blood mononuclear cells (BMC) (Maes et al. 2006) and lymphocytes (Scherzer et al. 2004) relative to non-demented control values. "
            }, 
            {
                "beginSection": "sections.3", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.3", 
                "offsetInBeginSection": 457, 
                "offsetInEndSection": 629, 
                "text": "We found that human BMC expressed a broad range of miRNAs, representing 20% of the 462 miRNA spotted on nitrocellulose membranes in the array format (Supplemental Table 2)."
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 1266, 
                "offsetInEndSection": 1402, 
                "text": ".We observed slightly different levels of miRNA expression between male and female BMC as illustrated by the heat map generated by GSEA "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2509, 
                "offsetInEndSection": 2886, 
                "text": "we screened 462 human miRNA (from let-7 family to miR-663) in BMC derived from well-characterized cases of mild sporadic AD and age-matched normal elderly control subjects and, based on predicted miRNA targets, ascertained whether the accruing data may account for the patterns of mRNA downregulation in Alzheimer BMC previously reported by our laboratories (Maes et al. 2006)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 622, 
                "offsetInEndSection": 809, 
                "text": "expression analysis of Sp1 and its regulatory microRNAs (hsa-miR-29b and hsa-miR-375) has been performed in peripheral blood mononuclear cells (PBMCs), together with Sp1 protein analysis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1308, 
                "offsetInEndSection": 1427, 
                "text": "Significantly decreased relative expression levels of hsa-miR-29b, but not of hsa-miR-375, were observed in AD patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1520, 
                "offsetInEndSection": 1684, 
                "text": "Sp1 and its regulatory hsa-miR-29b are deregulated in AD patients, possibly leading to aberrant production of downstream target genes involved in the pathogenesis. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528227", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 863, 
                "offsetInEndSection": 1282, 
                "text": "We previously observed that miR-137, -181c, -9, and 29a/b post-transcriptionally regulate SPT levels, and the corresponding miRNA levels in the blood sera are potential diagnostic biomarkers for AD. Here, we observe a negative correlation between cortical A\u03b242 and sera A\u03b242, and a positive correlation between cortical miRNA levels and sera miRNA levels suggesting their potential as noninvasive diagnostic biomarkers."
            }
        ], 
        "triples": [
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/10477709"
            }, 
            {
                "o": "http://purl.uniprot.org/pubmed/10339464", 
                "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                "s": "http://purl.uniprot.org/pubmed/10339464"
            }, 
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/10572112"
            }, 
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/11110714"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Are there any desmins present in plants?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/DESM_CHICK", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045098"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/20171226", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19026658", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18033728", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8752741", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1694790", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2659540", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7460905"
        ], 
        "exact_answer": "No", 
        "id": "5162e011298dcd4e51000049", 
        "ideal_answer": "No. Desmins are type III intermediate filament (IF) proteins that have been identified to date only in metazoa (human, Danio rerio, bovine). Desmins are also associated with severe forms of skeletal, cardiac and myofibrillar myopathies.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20171226", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 155, 
                "text": "Inherited mutations in the gene coding for the intermediate filament protein desmin have been demonstrated to cause severe skeletal and cardiac myopathies."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026658", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 228, 
                "text": "Mutations in the intermediate filament (IF) protein desmin cause severe forms of myofibrillar myopathy characterized by partial aggregation of the extrasarcomeric desmin cytoskeleton and structural disorganization of myofibrils."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18033728", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 135, 
                "offsetInEndSection": 479, 
                "text": "The family of 70 intermediate filament genes (including those encoding keratins, desmins, and lamins) is now known to be associated with a wide range of diverse diseases, at least 72 distinct human pathologies, including skin blistering, muscular dystrophy, cardiomyopathy, premature aging syndromes, neurodegenerative disorders, and cataract. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 75, 
                "text": "Mutations in desmin have been associated with a subset of human myopathies."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 99, 
                "text": "Characterization of a zebrafish (Danio rerio) desmin cDNA: an early molecular marker of myogenesis."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 93, 
                "text": "Acute effects of desmin mutations on cytoskeletal and cellular integrity in cardiac myocytes."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 293, 
                "text": "Desmin is a muscle-specific protein and a constitutive subunit of the intermediate filaments (IF) in skeletal, cardiac and smooth muscles. It is an early marker of skeletal muscle myogenesis. We have characterized a clone of desmin cDNA from an embryonic zebrafish (Danio rerio) cDNA library. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752741", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1055, 
                "offsetInEndSection": 1246, 
                "text": "Immunohistochemical investigation showed a positive reaction for smooth muscle actin and desmins in the spindle cells proliferated in the lymph nodes; no cytokeratin positivity was detected. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1694790", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 182, 
                "text": "We have raised monoclonal antibodies (Mab) to the Mr 55,000 desmin polypeptide, electrophoretically purified from cytoskeletal preparations of isolated bovine heart Purkinje fibers. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2659540", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 237, 
                "offsetInEndSection": 409, 
                "text": "Mesothelial and ovarian carcinoma cells could not be distinguished by (intermediate) filament typing, using monoclonal antibodies (MAbs) to keratins, vimentins and desmins."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7460905", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 201, 
                "text": "A fast and convenient procedure for the purification of polymerization-competent smooth-muscle desmin is described. Desmin from chicken gizzard and hog stomach were compared by fingerprint techniques. "
            }
        ], 
        "triples": [
            {
                "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0005882", 
                "p": "http://www.w3.org/2004/02/skos/core#broader", 
                "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0045098"
            }
        ], 
        "type": "yesno"
    }
]}
